EPHA2 and metastatic neoplasm: To test this hypothesis, CT26-EphA2 cells were implanted into both hind flanks of mice with the distal, non-illuminated tumor receiving a comparatively reduced tumor cell burden to model metastatic disease (Fig. 7A).